WO2009132354A2 - Method for confirming the presence of an analyte - Google Patents
Method for confirming the presence of an analyte Download PDFInfo
- Publication number
- WO2009132354A2 WO2009132354A2 PCT/US2009/041839 US2009041839W WO2009132354A2 WO 2009132354 A2 WO2009132354 A2 WO 2009132354A2 US 2009041839 W US2009041839 W US 2009041839W WO 2009132354 A2 WO2009132354 A2 WO 2009132354A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- nucleic acid
- contaminant
- dna
- multiplex pcr
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 239000012491 analyte Substances 0.000 title claims abstract description 19
- 238000012790 confirmation Methods 0.000 claims abstract description 20
- 230000000813 microbial effect Effects 0.000 claims abstract description 12
- 239000000523 sample Substances 0.000 claims description 69
- 238000003556 assay Methods 0.000 claims description 43
- 238000007403 mPCR Methods 0.000 claims description 25
- 108020004414 DNA Proteins 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 17
- 239000000356 contaminant Substances 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 15
- 244000005700 microbiome Species 0.000 claims description 14
- 239000012569 microbial contaminant Substances 0.000 claims description 12
- 239000013615 primer Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 231100000765 toxin Toxicity 0.000 claims description 12
- 239000003053 toxin Substances 0.000 claims description 12
- 239000011324 bead Substances 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 238000002944 PCR assay Methods 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000011109 contamination Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000002250 absorbent Substances 0.000 claims description 6
- 230000002745 absorbent Effects 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 239000011543 agarose gel Substances 0.000 claims description 4
- 239000013060 biological fluid Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 108020001019 DNA Primers Proteins 0.000 claims description 3
- 239000003155 DNA primer Substances 0.000 claims description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 238000005227 gel permeation chromatography Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000027455 binding Effects 0.000 claims description 2
- 238000004891 communication Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 7
- 241000588724 Escherichia coli Species 0.000 description 20
- 230000001717 pathogenic effect Effects 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 238000012216 screening Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 241000186781 Listeria Species 0.000 description 9
- 241000186779 Listeria monocytogenes Species 0.000 description 9
- 241000607142 Salmonella Species 0.000 description 8
- 108010079723 Shiga Toxin Proteins 0.000 description 8
- 235000013305 food Nutrition 0.000 description 6
- 230000002906 microbiologic effect Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002131 composite material Substances 0.000 description 3
- 231100000033 toxigenic Toxicity 0.000 description 3
- 230000001551 toxigenic effect Effects 0.000 description 3
- 241000193755 Bacillus cereus Species 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 101150010487 are gene Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- 241000607534 Aeromonas Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589986 Campylobacter lari Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 101710167241 Intimin Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000186806 Listeria grayi Species 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241000186780 Listeria ivanovii Species 0.000 description 1
- 241000186807 Listeria seeligeri Species 0.000 description 1
- 241000186814 Listeria welshimeri Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241000607000 Plesiomonas Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
Definitions
- the invention relates to the field of microbiology and more specifically relates to methods, articles, and kits for confirming the presence of an analyte. More particularly, the invention relates to a method and system that employs means to corroborate the findings of an initial positive assay result by a second robust alternative assay protocol.
- the present art of rapid screening suffers from the fact that either single signals are to be used to detect a given pathogen, in which case not all of the targets will be detected (they may not all have the target signal), or if multiple signals (multiplexes) are used to detect the pathogen/organism of interest, in matrixes such as food, water, environmental samples, and some clinical samples (such as urine and feces) where a diverse group of organisms are present, there is a distinct possibility that that the multiplex screen will detect a composite signal from more than one organism. For instance, if a food sample contains a non-toxigenic, eae negative E. coli 0157, an enteropathogenic E. coli, and an E.
- the present invention allows for rapid confirmation of the initial analyte test results. Typically the process takes from about one to about three hours. Furthermore, in a preferred embodiment, the process will allow for confirmation of the presence of a given microbial target in a mixed culture, or a mixed enrichment media, even when the competing organisms in the mix belong to related species, or are various biotypes of the same species.
- the methods of the present invention allow differentiation between E. coli 0157 and non-0157 Shiga toxin-producing E. coli in the same sample. Additionally, these methods can differentiate between Listeria monocytogenes and other Listeria species in the same sample. Also, these methods can identify multi-drug resistant salmonella from other Salmonella or other multi-drug resistant bacteria in the same sample.
- the invention solves the problems of the prior art by providing protocols to meet the performance criteria and generate a result rapidly so that subsequent decisions can be made in a timely manner.
- Various embodiments of the present invention are generally complementary to two broad classes of rapid screening methods which enrich a sample prior to application of an assay protocol.
- 'enrich' is understood to consist of the steps of adding growth media to a sample and incubating the sample at an appropriate temperature and for an appropriate period of time, so that the target organism is given an opportunity to reproduce and reach a concentration level commensurate with the detecting ability of the assay protocol.
- the first broad class of rapid screening methods which rely on enriching a sample use the polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- DNA primer templates are added which are composed of specific nucleotide sequences that complement known portions of genes which are unique to the target analyte organism.
- a DNA polymerase and nucleotides are added, and in vitro enzymatic replication of DNA occurs. As replicate DNA strands are generated, they serve as templates for the next cycle of replication.
- cycles are defined by alternating heating and cooling of the sample to allow the DNA to physically separate and join, with the thermal cycling conditions providing another means of enhancing selectivity.
- PCR With PCR it is possible to amplify a single or a few copies of a specific strand of DNA across several orders of magnitude, generating millions or more copies of the specific strand of DNA. Thereafter, the DNA is generally separated using agarose gel chromatography, and the DNA product, if present, is visualized by the application of a dye to the agarose gel.
- the second broad class of rapid screening methods which rely on enriching a sample are immunoassays, which rely on reactions between antibodies and their corresponding antigens which are unique to the target analyte organism.
- immunoassays which rely on reactions between antibodies and their corresponding antigens which are unique to the target analyte organism.
- one group of methods are enzyme-linked immunosorbent assays (ELISAs) in which an antigen associated with the target analyte organism is affixed to a surface, and then an antibody specific to that antigen is washed over the surface so that it can bind to the antigen.
- the antibody is linked to an enzyme which is capable of converting a substance that is added to some detectable signal.
- a second group of methods are immunochromatographic assays (also called lateral flow devices, or LFDs) in which a test sample flows through a matrix via capillary action.
- the sample encounters a visualizing reagent (e.g. colorimetric or fluorometric) which then migrates with the sample.
- a visualizing reagent e.g. colorimetric or fluorometric
- the sample encounters lines or zones which have been pretreated with either an antibody or antigen that binds to the target analyte, if present, and associated visualizing reagent.
- the presumptive positive sample will be subjected to PCR reaction(s) which are designed to amplify multiple targets
- the targets include at least two genes which are restricted mostly to or are unique in the target organism.
- At least one PCR reaction should target the conserved regions of the molecule, and another PCR reaction should target the specific variation(s) which are unique to the target organism.
- each PCR/multiplex confirmation reaction should be conducted with and without immunomagnetic separation, using specific antibodies to the target organism.
- Additional target genes for the target organism may be included to increase the confidence in the confirmation, or better define the target organism.
- each target gene two PCR reactions will be designed, each corresponding to different primer sequences. This will allow for redundancy and also protect against point mutation in primer sequences, and failure of one reaction.
- a method of confirming the presence of contamination in a sample includes contacting a first portion of the sample with a magnetic bead coated with an antibody that specifically recognizes a microorganism and providing a second portion of the sample that has not been contacted with the magnetic bead coated with an antibody that has contacted the first portion of the sample and assaying the first portion of the sample for the presence of a contaminant microorganism by 4-band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant, while separately assaying the first portion of the sample for the presence of a contaminant microorganism by 5 -band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant and one nucleic acid target specific to a suspected microbe, while separately assaying the second portion of the sample for the presence of a contaminant microorganism by 4-band multiplex PCR assay using PCR primers
- the sample may be contacted with a growth media to enrich the sample in a contaminant present in the sample.
- This aspect of the invention may be conducted on a sample that has been analyzed for the presence of a contaminant microorganism by 4-band multiplex PCR assay using PCR primers complementary to four gene targets associated with the microbial contaminant, prior to contacting a first portion of the sample with a magnetic bead.
- kits for performing an analytical test for detecting the presence of and distinguishing between E.Coli 0157 and non-0157 shinga toxin producing E. CoIi in a biological sample suspected of containing one or both.
- the kit includes an analytical test device having a plurality of wells, wherein the wells do not communicate with each other (wherein each well includes a filter stack, the filter stack including (i) a porous membrane having an upper surface and a lower surface; and (ii) an absorbent material, wherein the lower surface of the porous membrane and the absorbent material are in physical contact and in fluid communication, and wherein upon contact of a biological fluid sample suspected of containing one or both of E.Coli 0157 and non-0157 shinga toxin producing E.
- said fluid is able to flow through said membrane into said absorbent material, such that at least a portion of said E.Coli 0157 and non-0157 shinga toxin producing E. CoIi present in said biological fluid sample bind to said porous membrane); a first detection reagent capable of recognizing E.Coli 0157; a second detection reagent capable of recognizing non-0157 shinga toxin producing E. CoIi; and a reagent capable of generating a signal upon detection of one or both of E.Coli 0157 and non-0157 shinga toxin producing E. CoIi.
- Another aspect of the invention provides a method for obtaining confirmation of the presence of a microbial analyte in less than three hours, by adding growth media to a sample of bacteria cells believed to contain a target analyte organism and incubating the sample at an appropriate temperature for an appropriate period of time, so that the target organism is given an opportunity to reproduce and to reach a concentration level sufficient to detect a sought after analyte; lysing bacterial cells to release the DNA contained therein, adding DNA primer templates composed of specific nucleotide sequences that complement known portions of genes which are unique to the target analyte organism; adding DNA polymerase and nucleotides to achieve in vitro enzymatic replication of desired DNA pieces; amplifying said DNA pieces by several orders of magnitude to generate at least a million copies of the DNA piece; separating said DNA pieces by using agarose gel chromatography, and adding a dye to the DNA product to determine visually the presence of said DNA.
- Another aspect of the invention provides a method of detecting at least one substance of interest in a biological sample by providing a biological liquid sample suspected of comprising the substance(s) of interest; contacting the biological sample in a sufficient amount to with at least one specific binding pair member that is capable of binding, either directly or indirectly, the substance(s) of interest; and maintaining such contact for between about one and about 3 hours; and detecting the presence or absence of a complex comprising the specific binding pair member(s) and the substance(s) of interest, wherein the presence of at least one complex indicates the presence of at least one of the substances of interest in the biological sample.
- Patent publication No. 20080096236 to Koulchin Patent publication No. 20080096189 to Boone; 20080038769 to Bernardi; 20080026953 to Gala, as well as US Patent Nos. 7,255,992 to Ecker, et al;
- the present invention is drawn to methods of screeing and monitoring for microbial growth and contaminants including the use of secondary analysis methods needed for rapid screening and verification of primary or preliminary testing results.
- an initial or preliminary testing result may be obtained by sampling and/or testing a subject or good by any one of several testing methodologies as described in U.S. Patent Publication No. 200/0115824, such as "presence/absence" tests or a plurality of the same.
- Processes and systems to which the testing and verification methods of the instant application may be applicable include, but are not limited to: food production; manufacturing; processing; storage; transportation and distribution; with respect to microbial pathogens—process sanitation, environmental contaminants, and spoilage organisms; with respect to fermentation processes—determining purity of the seed stock and fermentation contaminants; aseptic processing (e.g., food and pharmaceutical; with respect to sterility and environmental control); water treatment (e.g., with respect to microbiological quality of the raw and treated water, and control of the organisms throughout the distribution system); wastewater treatment (e.g., with respect to microbiological quality of the treated wastewater and biosolids, control of the treatment process, control of the aerobic and anaerobic digestors, and assessment of the impact of the discharged wastewater and application of bio-solids on the receiving environments); control of microbial contaminants and assessment of their impact in the indoor environment and indoor air quality assessment studies; environmental microbiology (e.g., with respect to monitoring the microbiological quality of shellfish, shellfish beds and cultured aquatic organisms
- test methods that may include, but are not limited to, multiplex PCR reaction(s), DNA chips, dot blots, multi- and single-target lateral flow devices, and combinations thereof.
- assays suitable for detection of pathogenic or microbial contamination may include the use of immunoassays, nucleic acid amplification-based assays, PCR-based assays, nucleic acid hybridization- based assays, bio-sensor assays, immunostaining-microscopy-based assays, nucleic acid- array-based assays, DNA chip-based assays, bacteriophage-detection-based assays, classical microbiology-based assays, and chemical or biochemical assays based on the detection of compounds associated with particular target organisms or groups of target organisms, and combinations thereof.
- a 4-band multiplex PCR assay is used as an initial, rapid screening method.
- the four PCR assay targets are gene segments known to be associated with E. coli 0157. These assay targets are rfb, eae, stxl and stx2. After enrichment of a sample to allow the growth of the target organisms to the detection level, the enrichment is screened with the 4-band multiplex PCR assay.
- PCR assay contains targets for stxl, stx2, rfb, eae (one universal one gamma).
- targets for stxl, stx2, rfb, eae one universal one gamma.
- One of the multiplex PCR assays also contains an additional gene unique to 0157. Molecular Confirmation is done using the two multiplexes, with and without immunomagnetic separation using magnetic beads coated with anti-0157 antibodies.
- the key to separation of 0157 from non-0157 STEC and determination of whether there is a true 0157 versus a composite signal is determined by a comparison of the PCR assays with and without the beads and the fact that 0157 carries gamma eae. If a four band multiplex assay with the magnetic beads shows rfb, eae, and stx, this indicates that a true pathogenic 0157 E. coli in the enrichment, however if it only shows rfb, while the non-magnetic separated enrichment shows the rfb, eae, and stx, then we know that there is a non-toxigenic, eae-negative 0157 in the enrichment.
- the same principle is used for Listeria monocytogenes vs. Listeria species in the same enrichment and for toxigenic Bacillus cereus versus other Bacilli in the same enrichment, and for Salmonella/multi-drug resistant Salmonella versus a multi-drug resistant bacteria in the same enrichment.
- the same assay principles are used for other pathogenic, spoilage, indicators, biodegridative organisms, and pharmaceutical platform/producer strains of organisms.
- Immunomagnetic Separation is used to purify and concentrate the sample prior to conducting a confirmation 3 -band multiplex PCR assay; however, the immunomagnetic beads in this case are coated with antibodies which bind specifically to Salmonella spp.
- the pathogenic microbes Listeria spp. and Listeria monocytogenes are targeted using a 4-band multiplex PCR assay as a rapid screening method.
- Two of the PCR assay targets are gene segments known to be associated with LM, while the remaining two are known to be associated with Listeria spp. If a presumptive positive result is obtained using the rapid screening method for LM, a second 2-band multipex PCR assay is used to corroborate the presumptive positive result and provide confirmation. If a presumptive positive result is obtained for Listeria spp. another independent 2-band multipex PCR assay is used to corroborate the presumptive positive result and provide confirmation
- a seventh specific application again targets Listeria spp. and Listeria monocytogenes.
- IMS is used to purify and concentrate the sample prior to applying one or both of the confirmation 2-band multiplex PCR assays; however, the immunomagnetic beads in this case are coated with antibodies which bind specifically to Listeria spp., of which LM is one type.
- Another aspect of the present invention is directed to a rapid confirmation method for microorganisms, in mixed cultures or enrichment cultures.
- the method allows for rapid confirmation of the presence of single or multiple target organisms in the same mixture.
- the method has built in redundancy that increases the confidence in the results. It can also confirms and characterizes the organisms in a single step.
- microorganisms may include a microbe or pathogen such as Escherichia coli O157:H7 (E. coli O157:H7), enterohemorrhagic Escherichia coli (EHEC), enterotoxigenic Escherichia coli (ETEC), enteroinvasive Escherichia coli (EIEC), enterpathogenic Escherichia coli (EPEC), Salmonella, Listeria, Yersinis, Campylobacter, Clostridial species, Staphylococcus spp.; frank and opportunistic bacterial, fungal, viral, parsitic pathogens; indicator organisms including heterotrophes, generic E.
- a microbe or pathogen such as Escherichia coli O157:H7 (E. coli O157:H7), enterohemorrhagic Escherichia coli (EHEC), enterotoxigenic Escherichia coli (ETEC), enteroinvasive Escherichi
- coli total and fecal coliforms and enterococcus
- spoilage organisms including Pseudomonas
- indicator molecules including glial fibillary acid protein (GFAP), transmissable spongiform encephalopathy (TSE) agents (prions), including bovine spongiform encephalopathy (BSE) agents, scrapie, chronic wasting disease; and combinations thereof.
- Additional microbe sor pathogens are selected from the group consisting of Staph, aureus, Bacillus cereus, and Clostridium botulinum, Clostridium perfringes, Vibrio cholerae and V.
- Organisms that are particularly suited for testing in one or more aspects of the present invention include the following: Bacillus anthracis Campylobacter coli Campylobacter jujuni Campylobacter lari Coliforms E. coli 0157
- E. coli E. coli, Stx-producing (STEC) E. coli, Stx-producing with intimin E. coli, verotoxin producing
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides methods and kits for the rapid confirmation of an initial analyte test result. In a preferred embodiment, the process confirms the presence of a given microbial target in a mixed culture, or a mixed enrichment media, even when the competing organisms in the mix belong to related species, or are various biotypes of the same species.
Description
METHOD FOR CONFIRMING THE PRESENCE OF AN ANALYTE
CROSS REFERENCE TO RELATED APPLICATION This application claims the benefit of priority under 35 U. S. C. § 119(e) to U.S.
Provisional Patent Application No. 61/047,999 filed April 25, 2008, and is a continuation in part of U.S. Patent Application No. 11/107,458, filed April 15, 2005, which claims the benefit of priority under 35 U.S. C. § 119(e) to U.S. Provisional Patent Application No. 60/562,302, filed April 15, 2004. These priority applications are incorporated herein, in their entirety, by reference.
TECHNICAL FIELD
The invention relates to the field of microbiology and more specifically relates to methods, articles, and kits for confirming the presence of an analyte. More particularly, the invention relates to a method and system that employs means to corroborate the findings of an initial positive assay result by a second robust alternative assay protocol.
BACKGROUND OF INVENTION
Various approaches have been described for performing assays to determine the presence or concentration of a specific microbial analyte, such as pathogenic microbial contamination of food. Frequently, a two-step process is followed wherein a first, rapid screening method is used to obtain initial assay results with negative results accepted as is. When a positive result is obtained, it is characterized as a "presumptive positive" result until it can be confirmed by the application of a second, alternative assay protocol applied to the sample. This process is followed because it is highly desirable, and in some cases required by government regulation, to corroborate a positive result in order to prevent the unnecessary recall and needless disposal of material implicated as containing a pathogen, such as food products.
In order for an alternative analysis protocol to be effective for the purpose of confirmation, it must meet several performance criteria. It should be selective, i.e. it should correctly identify a sample as not containing a target pathogenic microbe when in fact the microbe is not present. It should be sensitive, i.e. it should correctly identify a
sample as containing a target pathogenic microbe when in fact the contaminant is present. It should have a low detection limit, i.e. it should give a positive result even when only a small number of target pathogen microbes are present.
Traditionally, these performance criteria have been met by applying cultural analysis protocols involving culture enrichment, selective and differential plating, and additional biochemical and serological methods. However, such cultural protocols suffer from the drawback that the time required to complete the analysis can easily extend over several days. This makes it difficult to acquire information in a timely manner upon which to base a decision regarding the recall or disposal of a perishable material implicated as potentially containing a pathogenic microbial contaminant by presumptive positive results obtained using a rapid screening method.
Thus, what is needed in the art is an alternative analysis method which meets the performance criteria necessary to corroborate presumptive positive results, and which can be completed rapidly enough to generate a result which can be acted upon in a timely manner.
Similarly, the present art of rapid screening suffers from the fact that either single signals are to be used to detect a given pathogen, in which case not all of the targets will be detected (they may not all have the target signal), or if multiple signals (multiplexes) are used to detect the pathogen/organism of interest, in matrixes such as food, water, environmental samples, and some clinical samples (such as urine and feces) where a diverse group of organisms are present, there is a distinct possibility that that the multiplex screen will detect a composite signal from more than one organism. For instance, if a food sample contains a non-toxigenic, eae negative E. coli 0157, an enteropathogenic E. coli, and an E. coli, producing Shiga toxin, and the sample is screened with a multiplex PCR that targets eae, rfb, and stx, to detect pathogenic E. coli 0157, then a composite signal consisting of three bands (eae, rfb, and stx) will be observed. In this instance, the data indicates that a pathogenic E. coli 0157 is detected in the sample, but in reality, the toxin and the eae signal come from two other organisms. The presently available techniques will consider the sample a presumptive positive and it is then subjected to culture confirmation which will take 3-5 days.
SUMMARY OF INVENTION
The present invention (referred to sometimes herein as Molecular Confirmation) allows for rapid confirmation of the initial analyte test results. Typically the process takes from about one to about three hours. Furthermore, in a preferred embodiment, the process will allow for confirmation of the presence of a given microbial target in a mixed culture, or a mixed enrichment media, even when the competing organisms in the mix belong to related species, or are various biotypes of the same species. For example, the methods of the present invention allow differentiation between E. coli 0157 and non-0157 Shiga toxin-producing E. coli in the same sample. Additionally, these methods can differentiate between Listeria monocytogenes and other Listeria species in the same sample. Also, these methods can identify multi-drug resistant salmonella from other Salmonella or other multi-drug resistant bacteria in the same sample.
The invention solves the problems of the prior art by providing protocols to meet the performance criteria and generate a result rapidly so that subsequent decisions can be made in a timely manner. Various embodiments of the present invention are generally complementary to two broad classes of rapid screening methods which enrich a sample prior to application of an assay protocol. Herein 'enrich' is understood to consist of the steps of adding growth media to a sample and incubating the sample at an appropriate temperature and for an appropriate period of time, so that the target organism is given an opportunity to reproduce and reach a concentration level commensurate with the detecting ability of the assay protocol.
The first broad class of rapid screening methods which rely on enriching a sample use the polymerase chain reaction (PCR). Generally, the enriched sample is lysed to release the DNA contained in organisms present. DNA primer templates are added which are composed of specific nucleotide sequences that complement known portions of genes which are unique to the target analyte organism. A DNA polymerase and nucleotides are added, and in vitro enzymatic replication of DNA occurs. As replicate DNA strands are generated, they serve as templates for the next cycle of replication. Generally, cycles are defined by alternating heating and cooling of the sample to allow the DNA to physically separate and join, with the thermal cycling conditions providing another means of enhancing selectivity. With PCR it is possible to amplify a single or a few copies of a specific strand of DNA across several orders of magnitude, generating millions or more copies of the specific strand of DNA. Thereafter, the DNA is generally separated using
agarose gel chromatography, and the DNA product, if present, is visualized by the application of a dye to the agarose gel.
The second broad class of rapid screening methods which rely on enriching a sample are immunoassays, which rely on reactions between antibodies and their corresponding antigens which are unique to the target analyte organism. For example, one group of methods are enzyme-linked immunosorbent assays (ELISAs) in which an antigen associated with the target analyte organism is affixed to a surface, and then an antibody specific to that antigen is washed over the surface so that it can bind to the antigen. The antibody is linked to an enzyme which is capable of converting a substance that is added to some detectable signal. A second group of methods are immunochromatographic assays (also called lateral flow devices, or LFDs) in which a test sample flows through a matrix via capillary action. The sample encounters a visualizing reagent (e.g. colorimetric or fluorometric) which then migrates with the sample. The sample encounters lines or zones which have been pretreated with either an antibody or antigen that binds to the target analyte, if present, and associated visualizing reagent.
Various embodiments of the present invention rely on applying one or more of seven principles to define a rapid confirmatory analysis protocol. These principles are:
(1) The presumptive positive sample will be subjected to PCR reaction(s) which are designed to amplify multiple targets (2) The targets include at least two genes which are restricted mostly to or are unique in the target organism.
(3) When, in any one of the target genes, there are variations in the sequences among the target organisms and closely related biotypes, at least one PCR reaction should target the conserved regions of the molecule, and another PCR reaction should target the specific variation(s) which are unique to the target organism.
(4) In it's preferred embodiment, each PCR/multiplex confirmation reaction should be conducted with and without immunomagnetic separation, using specific antibodies to the target organism.
(5) Additional target genes for the target organism may be included to increase the confidence in the confirmation, or better define the target organism.
(6) In it's preferred embodiment for each target gene, two PCR reactions will be designed, each corresponding to different primer sequences. This will allow for
redundancy and also protect against point mutation in primer sequences, and failure of one reaction.
(7) Other confirmatory rapid tests for specific targets, such as immunochemical test (lateral flow devices), toxin assays, and specific biochemicals may also be used to complement the molecular confirmation reactions.
In a specific aspect of the invention, a method of confirming the presence of contamination in a sample is provided that includes contacting a first portion of the sample with a magnetic bead coated with an antibody that specifically recognizes a microorganism and providing a second portion of the sample that has not been contacted with the magnetic bead coated with an antibody that has contacted the first portion of the sample and assaying the first portion of the sample for the presence of a contaminant microorganism by 4-band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant, while separately assaying the first portion of the sample for the presence of a contaminant microorganism by 5 -band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant and one nucleic acid target specific to a suspected microbe, while separately assaying the second portion of the sample for the presence of a contaminant microorganism by 4-band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant, while separately assaying the second portion of the sample for the presence of a contaminant microorganism by 5 -band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant and one nucleic acid target specific to a suspected microbe and comparing the results of the PCR assays wherein: a) the detection of three nucleic acid targets in the four band multiplex PCR assay conducted on the first portion of the sample is indicative of microbial contamination of the sample, or b) the detection of one nucleic acid target in the four band multiplex PCR assay conducted on the first portion of the sample and the detection of three nucleic acid targets in the four band multiplex PCR assay conducted on the second portion of the sample is indicative of is indicative of the absence of the suspected microbe. In this aspect of the invention, the sample may be contacted with a growth media to enrich the sample in a contaminant present in the sample. This aspect of the invention may be conducted on a sample that has been analyzed for the presence of a contaminant microorganism by 4-band multiplex PCR
assay using PCR primers complementary to four gene targets associated with the microbial contaminant, prior to contacting a first portion of the sample with a magnetic bead.
Another aspect of the invention provides a kit for performing an analytical test for detecting the presence of and distinguishing between E.Coli 0157 and non-0157 shinga toxin producing E. CoIi in a biological sample suspected of containing one or both. The kit includes an analytical test device having a plurality of wells, wherein the wells do not communicate with each other (wherein each well includes a filter stack, the filter stack including (i) a porous membrane having an upper surface and a lower surface; and (ii) an absorbent material, wherein the lower surface of the porous membrane and the absorbent material are in physical contact and in fluid communication, and wherein upon contact of a biological fluid sample suspected of containing one or both of E.Coli 0157 and non-0157 shinga toxin producing E. CoIi with said porous membrane, said fluid is able to flow through said membrane into said absorbent material, such that at least a portion of said E.Coli 0157 and non-0157 shinga toxin producing E. CoIi present in said biological fluid sample bind to said porous membrane); a first detection reagent capable of recognizing E.Coli 0157; a second detection reagent capable of recognizing non-0157 shinga toxin producing E. CoIi; and a reagent capable of generating a signal upon detection of one or both of E.Coli 0157 and non-0157 shinga toxin producing E. CoIi.
Another aspect of the invention provides a method for obtaining confirmation of the presence of a microbial analyte in less than three hours, by adding growth media to a sample of bacteria cells believed to contain a target analyte organism and incubating the sample at an appropriate temperature for an appropriate period of time, so that the target organism is given an opportunity to reproduce and to reach a concentration level sufficient to detect a sought after analyte; lysing bacterial cells to release the DNA contained therein, adding DNA primer templates composed of specific nucleotide sequences that complement known portions of genes which are unique to the target analyte organism; adding DNA polymerase and nucleotides to achieve in vitro enzymatic replication of desired DNA pieces; amplifying said DNA pieces by several orders of magnitude to generate at least a million copies of the DNA piece;
separating said DNA pieces by using agarose gel chromatography, and adding a dye to the DNA product to determine visually the presence of said DNA.
Another aspect of the invention provides a method of detecting at least one substance of interest in a biological sample by providing a biological liquid sample suspected of comprising the substance(s) of interest; contacting the biological sample in a sufficient amount to with at least one specific binding pair member that is capable of binding, either directly or indirectly, the substance(s) of interest; and maintaining such contact for between about one and about 3 hours; and detecting the presence or absence of a complex comprising the specific binding pair member(s) and the substance(s) of interest, wherein the presence of at least one complex indicates the presence of at least one of the substances of interest in the biological sample.
The following references are incorporated herein in their entireties to enable one of skill in the art to appreciate various aspects of the present invention: Patent publication No. 20080096236 to Koulchin; 20080096189 to Boone; 20080038769 to Bernardi; 20080026953 to Gala, as well as US Patent Nos. 7,255,992 to Ecker, et al;
7,226,739 to Ecker, et al.; 7,052,831 to Fletcher, et al.
DESCRIPTION OF EMBODIMENTS
The present invention is drawn to methods of screeing and monitoring for microbial growth and contaminants including the use of secondary analysis methods needed for rapid screening and verification of primary or preliminary testing results. In conducting testing for microbial growth or contamination, an initial or preliminary testing result may be obtained by sampling and/or testing a subject or good by any one of several testing methodologies as described in U.S. Patent Publication No. 200/0115824, such as "presence/absence" tests or a plurality of the same. Processes and systems to which the testing and verification methods of the instant application may be applicable include, but are not limited to: food production; manufacturing; processing; storage; transportation and distribution; with respect to microbial pathogens—process sanitation, environmental contaminants, and spoilage organisms; with respect to fermentation processes—determining purity of the seed stock and fermentation contaminants; aseptic processing (e.g., food and pharmaceutical; with respect to sterility and environmental control); water treatment (e.g., with respect to microbiological quality of the raw and treated water, and control of the organisms
throughout the distribution system); wastewater treatment (e.g., with respect to microbiological quality of the treated wastewater and biosolids, control of the treatment process, control of the aerobic and anaerobic digestors, and assessment of the impact of the discharged wastewater and application of bio-solids on the receiving environments); control of microbial contaminants and assessment of their impact in the indoor environment and indoor air quality assessment studies; environmental microbiology (e.g., with respect to monitoring the microbiological quality of shellfish, shellfish beds and cultured aquatic organisms, assessing the microbiological quality of recreational waters and swimming beaches, assessing the microbiological quality of bodies of water, conducting impact assessment of point and non-point-sources); feed microbiology (e.g., in determining the microbiological quality and safety of the feed); soil microbiology (e.g., in assessing the overall microbiology and population structure of soil organisms, in assessing target organisms that can indicate environmental contamination or organic and inorganic reservoirs (e.g., oil fields)). If a presumptive positive result is obtained using the rapid screening method, molecular confirmation is conducted using test methods that may include, but are not limited to, multiplex PCR reaction(s), DNA chips, dot blots, multi- and single-target lateral flow devices, and combinations thereof. In preferred aspects, assays suitable for detection of pathogenic or microbial contamination may include the use of immunoassays, nucleic acid amplification-based assays, PCR-based assays, nucleic acid hybridization- based assays, bio-sensor assays, immunostaining-microscopy-based assays, nucleic acid- array-based assays, DNA chip-based assays, bacteriophage-detection-based assays, classical microbiology-based assays, and chemical or biochemical assays based on the detection of compounds associated with particular target organisms or groups of target organisms, and combinations thereof.
In a specific application for the target analyte organism E. coli 0157, a 4-band multiplex PCR assay is used as an initial, rapid screening method. The four PCR assay targets are gene segments known to be associated with E. coli 0157. These assay targets are rfb, eae, stxl and stx2. After enrichment of a sample to allow the growth of the target organisms to the detection level, the enrichment is screened with the 4-band multiplex PCR assay.
If a presumptive positive result is obtained using the rapid screening method, molecular confirmation is conducted using two other multiplex PCR reactions (one with
four targets and one with five targets). Each PCR assay contains targets for stxl, stx2, rfb, eae (one universal one gamma). One of the multiplex PCR assays also contains an additional gene unique to 0157. Molecular Confirmation is done using the two multiplexes, with and without immunomagnetic separation using magnetic beads coated with anti-0157 antibodies.
The key to separation of 0157 from non-0157 STEC and determination of whether there is a true 0157 versus a composite signal, is determined by a comparison of the PCR assays with and without the beads and the fact that 0157 carries gamma eae. If a four band multiplex assay with the magnetic beads shows rfb, eae, and stx, this indicates that a true pathogenic 0157 E. coli in the enrichment, however if it only shows rfb, while the non-magnetic separated enrichment shows the rfb, eae, and stx, then we know that there is a non-toxigenic, eae-negative 0157 in the enrichment.
The same principle is used for Listeria monocytogenes vs. Listeria species in the same enrichment and for toxigenic Bacillus cereus versus other Bacilli in the same enrichment, and for Salmonella/multi-drug resistant Salmonella versus a multi-drug resistant bacteria in the same enrichment. The same assay principles are used for other pathogenic, spoilage, indicators, biodegridative organisms, and pharmaceutical platform/producer strains of organisms.
A fifth specific application again targets Salmonella spp. Immunomagnetic Separation (IMS) is used to purify and concentrate the sample prior to conducting a confirmation 3 -band multiplex PCR assay; however, the immunomagnetic beads in this case are coated with antibodies which bind specifically to Salmonella spp.
In a sixth specific application, the pathogenic microbes Listeria spp. and Listeria monocytogenes (LM) are targeted using a 4-band multiplex PCR assay as a rapid screening method. Two of the PCR assay targets are gene segments known to be associated with LM, while the remaining two are known to be associated with Listeria spp. If a presumptive positive result is obtained using the rapid screening method for LM, a second 2-band multipex PCR assay is used to corroborate the presumptive positive result and provide confirmation. If a presumptive positive result is obtained for Listeria spp. another independent 2-band multipex PCR assay is used to corroborate the presumptive positive result and provide confirmation
A seventh specific application again targets Listeria spp. and Listeria monocytogenes. IMS is used to purify and concentrate the sample prior to applying one or
both of the confirmation 2-band multiplex PCR assays; however, the immunomagnetic beads in this case are coated with antibodies which bind specifically to Listeria spp., of which LM is one type.
Another aspect of the present invention is directed to a rapid confirmation method for microorganisms, in mixed cultures or enrichment cultures. The method allows for rapid confirmation of the presence of single or multiple target organisms in the same mixture. The method has built in redundancy that increases the confidence in the results. It can also confirms and characterizes the organisms in a single step.
These microorganisms may include a microbe or pathogen such as Escherichia coli O157:H7 (E. coli O157:H7), enterohemorrhagic Escherichia coli (EHEC), enterotoxigenic Escherichia coli (ETEC), enteroinvasive Escherichia coli (EIEC), enterpathogenic Escherichia coli (EPEC), Salmonella, Listeria, Yersinis, Campylobacter, Clostridial species, Staphylococcus spp.; frank and opportunistic bacterial, fungal, viral, parsitic pathogens; indicator organisms including heterotrophes, generic E. coli, total and fecal coliforms and enterococcus; spoilage organisms including Pseudomonas; indicator molecules including glial fibillary acid protein (GFAP), transmissable spongiform encephalopathy (TSE) agents (prions), including bovine spongiform encephalopathy (BSE) agents, scrapie, chronic wasting disease; and combinations thereof. Additional microbe sor pathogensare selected from the group consisting of Staph, aureus, Bacillus cereus, and Clostridium botulinum, Clostridium perfringes, Vibrio cholerae and V. parahemolyticus, Yersinia enterocolitica, Yersinia pestis, Brucella. Francisella, Aeromonas and Plesiomonas, Citrobacter, Enterobacter, Klebsiella, Morganella, Proteus, Providencia, Serratia, and Shigella.
Organisms that are particularly suited for testing in one or more aspects of the present invention include the following: Bacillus anthracis Campylobacter coli Campylobacter jujuni Campylobacter lari Coliforms E. coli 0157
E. coli, Stx-producing (STEC) E. coli, Stx-producing with intimin
E. coli, verotoxin producing
Listeria grayi
Listeria innocua
Listeria ivanovii Listeria monocytogenes
Listeria seeligeri
Listeria spp.
Listeria welshimeri
Salmonella spp. Staphylococcal enterotoxins A, B3 C (C 1 , C2, C3), D and E
Staphylococcus aureus
Yeast and mold
Each publication or patent cited herein is incorporated herein by reference in its entirety. The foregoing description of the present invention has been presented for purposes of illustration and description. Furthermore, the description is not intended to limit the invention to the form disclosed herein. Consequently, variations and modifications commensurate with the above teachings, and the skill or knowledge of the relevant art, are within the scope of the present invention. The embodiments described hereinabove are further intended to explain the best mode known for practicing the invention and to enable others skilled in the art to utilize the invention in such, or other, embodiments and with various modifications required by the particular applications or uses of the present invention. It is intended that the appended claims be construed to include alternative embodiments to the extent permitted by the prior art.
Claims
1. A method of confirming the presence of contamination in a sample comprising contacting a first portion of the sample with a magnetic bead coated with an antibody that specifically recognizes a microorganism; providing a second portion of the sample that has not been contacted with the magnetic bead coated with an antibody that has contacted the first portion of the sample; assaying the first portion of the sample for the presence of a contaminant microorganism by 4-band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant; separately assaying the first portion of the sample for the presence of a contaminant microorganism by 5 -band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant and one nucleic acid target specific to a suspected microbe; separately assaying the second portion of the sample for the presence of a contaminant microorganism by 4-band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant; separately assaying the second portion of the sample for the presence of a contaminant microorganism by 5-band multiplex PCR assay using PCR primers complementary to four nucleic acid targets indicative of microbial contaminant and one nucleic acid target specific to a suspected microbe; comparing the results of the PCR assays wherein: a) the detection of three nucleic acid targets in the four band multiplex PCR assay conducted on the first portion of the sample is indicative of microbial contamination of the sample, b) the detection of one nucleic acid target in the four band multiplex PCR assay conducted on the first portion of the sample and the detection of three nucleic acid targets in the four band multiplex PCR assay conducted on the second portion of the sample is indicative of is indicative of the absence of the suspected microbe.
2. The method of Claim 1, wherein the sample is contacted with a growth media to enrich the sample in a contaminant present in the sample.
3. The method of Claim 1, wherein the sample has been analyzed for the presence of a contaminant microorganism by 4-band multiplex PCR assay using PCR primers complementary to four gene targets associated with the microbial contaminant, prior to contacting a first portion of the sample with a magnetic bead.
4. A kit for performing an analytical test for detecting the presence of and distinguishing between E. CoIi 0157 and non-0157 shinga toxin producing E. CoIi in a biological sample suspected of containing one or both, the kit comprising: (a) an analytical test device having a plurality of wells, wherein the wells do not communicate with each other; and wherein each well comprises: a filter stack, the filter stack comprising:
(i) a porous membrane having an upper surface and a lower surface; and (ii) an absorbent material, wherein said lower surface of said porous membrane and said absorbent material are in physical contact and in fluid communication, and wherein upon contact of a biological fluid sample suspected of containing one or both of E.Coli 0157 and non-0157 shinga toxin producing E. CoIi with said porous membrane, said fluid is able to flow through said membrane into said absorbent material, such that at least a portion of said E.Coli 0157 and non-0157 shinga toxin producing E. CoIi present in said biological fluid sample bind to said porous membrane;
(b) a first detection reagent capable of recognizing E.Coli 0157;
(c) a second detection reagent capable of recognizing non-0157 shinga toxin producing E. CoIi; and (d) a reagent capable of generating a signal upon detection of one or both of E.Coli
0157 and non-0157 shinga toxin producing E. CoIi.
5. A method for obtaining confirmation of the presence of a microbial analyte in less than three hours, comprising: adding growth media to a sample of bacteria cells believed to contain a target analyte organism and incubating the sample at an appropriate temperature for an appropriate period of time, so that said target organism is given an opportunity to reproduce and to reach a concentration level sufficient to detect a sought after analyte; lysing bacterial cells to release the DNA contained therein, adding DNA primer templates composed of specific nucleotide sequences that complement known portions of genes which are unique to the target analyte organism; adding DNA polymerase and nucleotides to achieve in vitro enzymatic replication of desired DNA pieces; amplifying said DNA pieces by several orders of magnitude to generate at least a million copies of the DNA piece; separating said DNA pieces by using agarose gel chromatography, and adding a dye to the DNA product to determine visually the presence of said
DNA.
6. A method of detecting at least one substance of interest in a biological sample, said method comprising: providing a biological liquid sample suspected of comprising the substance(s) of interest; contacting the biological sample in a sufficient amount to with at least one specific binding pair member that is capable of binding, either directly or indirectly, the substance(s) of interest; and maintaining such contact for between about one and about 3 hours; and detecting the presence or absence of a complex comprising the specific binding pair member(s) and the substance(s) of interest, wherein the presence of at least one complex indicates the presence of at least one of the substances of interest in the biological sample.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4799908P | 2008-04-25 | 2008-04-25 | |
US61/047,999 | 2008-04-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009132354A2 true WO2009132354A2 (en) | 2009-10-29 |
WO2009132354A3 WO2009132354A3 (en) | 2010-01-07 |
Family
ID=41217454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/041839 WO2009132354A2 (en) | 2008-04-25 | 2009-04-27 | Method for confirming the presence of an analyte |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009132354A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111133113A (en) * | 2017-09-21 | 2020-05-08 | 贝克顿·迪金森公司 | High dynamic range assay in hazardous contaminants testing |
USD1066729S1 (en) | 2017-09-21 | 2025-03-11 | Becton, Dickinson And Company | Collection device |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115074A1 (en) * | 2001-02-20 | 2002-08-22 | Nanibhushan Dattagupta | Methods and compositions for analyzing nucleic acids |
US20050170346A1 (en) * | 2001-12-19 | 2005-08-04 | Quantibact A/S C/O Novi A/S | Method and a kit for determination of a microbial count |
US20060115824A1 (en) * | 2004-04-15 | 2006-06-01 | Institute For Environmental Health, Inc. | Trend analysis and statistical process control using multitargeted screening assays |
US20060205040A1 (en) * | 2005-03-03 | 2006-09-14 | Rangarajan Sampath | Compositions for use in identification of adventitious viruses |
US20070287156A1 (en) * | 2004-09-21 | 2007-12-13 | Nader Pourmand | DNA fingerprinting using a branch migration assay |
US20080003564A1 (en) * | 2006-02-14 | 2008-01-03 | Iquum, Inc. | Sample processing |
-
2009
- 2009-04-27 WO PCT/US2009/041839 patent/WO2009132354A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115074A1 (en) * | 2001-02-20 | 2002-08-22 | Nanibhushan Dattagupta | Methods and compositions for analyzing nucleic acids |
US20050170346A1 (en) * | 2001-12-19 | 2005-08-04 | Quantibact A/S C/O Novi A/S | Method and a kit for determination of a microbial count |
US20060115824A1 (en) * | 2004-04-15 | 2006-06-01 | Institute For Environmental Health, Inc. | Trend analysis and statistical process control using multitargeted screening assays |
US20070287156A1 (en) * | 2004-09-21 | 2007-12-13 | Nader Pourmand | DNA fingerprinting using a branch migration assay |
US20060205040A1 (en) * | 2005-03-03 | 2006-09-14 | Rangarajan Sampath | Compositions for use in identification of adventitious viruses |
US20080003564A1 (en) * | 2006-02-14 | 2008-01-03 | Iquum, Inc. | Sample processing |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111133113A (en) * | 2017-09-21 | 2020-05-08 | 贝克顿·迪金森公司 | High dynamic range assay in hazardous contaminants testing |
CN111133113B (en) * | 2017-09-21 | 2024-03-29 | 贝克顿·迪金森公司 | High dynamic range assay in hazardous contaminant testing |
USD1066729S1 (en) | 2017-09-21 | 2025-03-11 | Becton, Dickinson And Company | Collection device |
Also Published As
Publication number | Publication date |
---|---|
WO2009132354A3 (en) | 2010-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hameed et al. | Conventional and emerging detection techniques for pathogenic bacteria in food science: A review | |
Wang et al. | Culture‐independent rapid detection methods for bacterial pathogens and toxins in food matrices | |
Valderrama et al. | Commercially available rapid methods for detection of selected food-borne pathogens | |
Gilbride et al. | Molecular techniques in wastewater: understanding microbial communities, detecting pathogens, and real-time process control | |
Dunbar et al. | Quantitative, multiplexed detection of bacterial pathogens: DNA and protein applications of the Luminex LabMAP™ system | |
Glynn et al. | Current and emerging molecular diagnostic technologies applicable to bacterial food safety | |
Jasson et al. | Alternative microbial methods: An overview and selection criteria | |
Dwivedi et al. | Detection of pathogens in foods: the current state-of-the-art and future directions | |
Lin et al. | Immuno-and nucleic acid-based current technique for Salmonella detection in food | |
Köster et al. | Analytical methods for microbiological water quality testing | |
US20200340993A1 (en) | Method for confirming the presence of an analyte | |
Tambi et al. | Methods for detection and enumeration of coliforms in drinking water: a review | |
Feng | Emergence of rapid methods for identifying microbial pathogens in foods | |
Vasavada et al. | Conventional and novel rapid methods for detection and enumeration of microorganisms | |
Akkina et al. | Tools for rapid detection and control of foodborne microbial pathogens | |
Paton et al. | Methods for detection of STEC in humans: an overview | |
Li et al. | Combination of direct boiling and glass beads increases the purity and accuracy of bacterial DNA extraction | |
Cimaglia et al. | Detection of L. monocytogenes in enrichment cultures by immunoseparation and immunosensors | |
Yousef | Detection of bacterial pathogens in different matrices: current practices and challenges | |
WO2009132354A2 (en) | Method for confirming the presence of an analyte | |
Weigl et al. | Fully integrated multiplexed lab-on-a-card assay for enteric pathogens | |
Brehm-Stecher et al. | Rapid methods for detection of Listeria | |
McCarthy | Immunological techniques: ELISA | |
van Amerongen et al. | Simple and rapid bacterial protein and DNA diagnostic methods based on signal generation with colloidal carbon particles | |
Majumdar et al. | Detection of food borne pathogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09734138 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09734138 Country of ref document: EP Kind code of ref document: A2 |